Theorem Clinical Research

R&D Trends

International Progressive MS Alliance awards $28.4M in research grants

Tuesday, September 16, 2014 08:00 AM

The International Progressive MS Alliance has awarded its first round of 22 research grants to investigators in nine countries, with the goal of removing barriers to developing treatments for progressive multiple sclerosis (MS). The alliance is a worldwide collaborative focused on finding solutions to progressive forms of multiple sclerosis that have so far eluded the scientific community.

More... »


Synergistix, MedPro Systems partner

Tuesday, September 16, 2014 07:55 AM

Synergistix, a Sunrise, Fla.-based provider of customer relationship management (CRM) solutions for life sciences, has partnered with MedPro Systems, an Arlington, N.J.-based healthcare licensing solution for pharmaceutical and device industries.

More... »


Cellerant awarded $47.5M for development of CLT-008 for acute radiation syndrome

Friday, September 12, 2014 01:16 PM

Cellerant Therapeutics, a California biotechnology company developing novel hematopoietic stem cell-based cellular and antibody therapies for blood disorders and cancer, has been awarded $47.5 million under a second option exercised by the Biomedical Advanced Research and Development Authority (BARDA) in the office of the assistant secretary for preparedness and response of the department of Health and Human Services.

More... »

Gates Foundation commits $50M to support emergency response to Ebola

Friday, September 12, 2014 01:13 PM

The Bill & Melinda Gates Foundation plans to commit $50 million to support the scale up of emergency efforts to contain the Ebola outbreak in West Africa and interrupt transmission of the virus.

More... »

PhRMA: 44 medicines and vaccines in development for HIV/AIDS

Friday, September 12, 2014 01:13 PM

America’s biopharmaceutical research companies currently are developing 44 medicines and vaccines for HIV/AIDS treatment and prevention, according to the latest Medicines in Development report by the Washington, D.C.-based Pharmaceutical Research and Manufacturers of America (PhRMA). A second report, The Value of Innovation in HIV/AIDS Therapy, a PhRMA-sponsored white paper by Boston Healthcare Associates (BHA), highlights the progress in HIV/AIDS treatment and its impact on patients afflicted with the disease. 

More... »

Evotec, CHDI Foundation extend ongoing Huntington's disease collaboration

Friday, September 12, 2014 01:00 PM

The CHDI Foundation, a U.S. privately-funded nonprofit biomedical research organization, has extended and restated its collaboration with Evotec, a drug discovery solutions company based in Germany, through 2017. The collaboration, which aims to find new treatments for Huntington's disease, an inherited neurodegenerative disorder, means CHDI will fund up to 52 full-time scientists at Evotec over the next three years.

More... »

SRI International, Nobelpharma partner on endometriosis treatment

Thursday, September 11, 2014 01:41 PM

SRI International, a California-based independent nonprofit research institute, and Nobelpharma, a Japanese pharmaceutical company, have entered into a licensing agreement to test SR16234, an SRI drug candidate that may be effective in treating endometriosis. SR16234 is a member of a class of drugs known as selective estrogen receptor modulators (SERMs) that regulate the effects of the hormone estrogen.

More... »

MabVax Therapeutics, MSKCC and Juno Therapeutics ink agreement

Thursday, September 11, 2014 01:38 PM

MabVax Therapeutics Holdings, a San Diego-based clinical stage oncology drug development company, has entered into agreements with New York City’s Memorial Sloan-Kettering Cancer Center (MSKCC) and Seattle-based Juno Therapeutics for the development of novel therapeutic products using antibody targeting sequences derived from the fully-human antibodies discovered using the company's internally developed antibody discovery platform.

More... »

PharmAthene awarded $28.1M to develop thermostable anthrax vaccine

Thursday, September 11, 2014 01:36 PM

PharmAthene, an Annapolis, Md.-based biodefense company developing medical countermeasures against biological and chemical threats, has announced the National Institute of Allergy and Infectious Diseases (NIAID), part of the NIH, has awarded the company a contract, valued at up to $28.1 million if all contract options are exercised, for the development of a next-generation anthrax vaccine based on the company's proprietary rPA anthrax vaccine technology platform.

More... »

Report: Psoriatic arthritis market will reach more than $3.5B in 2023

Thursday, September 11, 2014 01:28 PM

The market for psoriatic arthritis (PsA) therapies will grow nearly 66%, increasing to $3.7 billion in 2023, due to the continued uptake of premium-price biologics and novel therapies expected to launch during the 2013 to 2023 forecast period, according to Burlington, Mass.-based Decision Resources Group.

More... »

Subscribe to The CenterWatch Monthly
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

October 20

Toronto Star, with FDA data, exposes weaknesses in Health Canada's clinical trial, inspection oversight

Crowdsourcing effort aims to fund updated online social media guide for sponsor interaction with patients

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

September

Today's fastest, most economical sponsors
Standout sponsors reveal how they shorten regulatory, clinical cycle times

From the trenches: Sites' eye view of state of the industry
CW’s first site focus groups uncover frustration with 'progress,' but a passion for their mission

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

August

Reality of costs and impact rain on Sunshine Act
Concerns mount over compliance burden on CROs, sponsors, unanticipated consequences for research

Cloud computing expanding into all areas of clinical trial conduct
Benefits outweigh the complexities, challenges of finding right vendors

Already a subscriber?
Log in to your digital subscription.

Purchase the August issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs